Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SINGAPORE EXCHANGE  >  Luye Pharma Group Ltd    LUYE   BMG5722Z1014

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

LUYE PHRM : Exercise Of The Call Option By Luye Biotech (Singapore) Pte Ltd Under The Investment Agreement To Acquire All The Shares Held By Biomedical Sciences Investment Fund Pte Ltd In The Issued Share Capital Of A-Bio Pharma Pte Ltd

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 12:35pm CET

LUYE PHARMA GROUP LTD.

(INCORPORATED IN BERMUDA)

EXERCISE OF THE CALL OPTION BY LUYE BIOTECH (SINGAPORE) PTE LTD UNDER THE INVESTMENT AGREEMENT TO ACQUIRE ALL THE SHARES HELD BY BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD IN THE ISSUED SHARECAPITAL OF A-BIO PHARMA PTE LTD

Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company?s announcement dated

30 July 2010 in relation to the Strategic Investment in A-Bio Pharma Pte Ltd by Luye-Biotech

(Singapore) Pte Ltd.

The Board of Directors of Luye Pharma Group Ltd. (?Luye? or ?the Company?) is pleased to announce that Luye Biotech, a wholly-owned subsidiary of the Company, has exercised the Call Option under the Investment Agreement to acquire all of BMSIF?s shares comprising (i) one (1) ordinary share and (ii) 2,500,000 preference shares (Series B Preferred Shares) (collectively known as the ?Call Option Shares?) in A-Bio Pharma Pte Ltd (?A-Bio?) at a Option Consideration of S$2,750,000.

When the acquisition is completed, the Company will own 100% of the entire issued share capital of A-Bio through another wholly-owned subsidiary, Shandong Luye Pharmaceutical Co. Ltd.

The Option Consideration will funded by internal resources and is not expected to have any material impact on the net tangible assets per share and earnings per share of the Company for the current financial year ending 31 December 2011.

None of the Directors or controlling shareholders has any interest, directly or indirectly, in the transaction.

By Order of the Board

Liu Dianbo

Executive Chairman

Date: 25 July 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUYE PHARMA GROUP LTD
12/02 LUYE PHARMA : China`s Luye Pharma Completes Acquistion Of Acino`s Transdermal Dr..
12/01 LUYE PHARMA : Chinas Luye Pharma acquires Swiss Acino unit for $260m
12/01 LUYE PHARMA : Announces the Completion of Acquisition of Acino's Transdermal Dru..
12/01 LUYE PHARMA : Major step forward in becoming a leading global pharmaceutical ent..
12/01 LUYE PHARMA : Announces the Completion of Acquisition of Acino's Transdermal Dru..
11/30 LUYE PHARMA : Acino closes the deal to divest its patch business to Luye Pharma ..
11/30 LUYE PHARMA : Discloseable transaction completion of acquisition of acino's tran..
11/17 LUYE PHARMA : Nodded for Clinic Test
11/17 LUYE PHARMA : Announcement
11/16 MAN WAH : Clarifies Investment in Le.com
More news
Sector news : Generic Pharmaceuticals
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Generic Pharmaceuticals
Advertisement
Financials ( CNY)
Sales 2016 2 856 M
EBIT 2016 981 M
Net income 2016 881 M
Finance 2016 1 817 M
Yield 2016 -
P/E ratio 2016 17,08
P/E ratio 2017 14,15
EV / Sales 2016 4,63x
EV / Sales 2017 3,80x
Capitalization 15 031 M
More Financials
Chart LUYE PHARMA GROUP LTD
Duration : Period :
Luye Pharma Group Ltd Technical Analysis Chart | LUYE | BMG5722Z1014 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 5,80  CNY
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Dian Bo Liu Executive Chairman & Chief Executive Officer
Yuan Chong Liu Chief Financial Officer
You Xin Li Vice President, Head-Research & Development
Hui Xian Yuan Executive Director
Rong Bing Yang Vice Executive Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LUYE PHARMA GROUP LTD0.00%2 184
SUN PHARMACEUTICAL IND..-11.92%25 404
OTSUKA HOLDINGS CO LTD3.32%22 196
ONO PHARMACEUTICAL CO...-42.62%13 002
ASPEN PHARMACARE HOLDI..-8.88%9 268
SHANGHAI FOSUN PHARMAC..-1.83%7 929
More Results